We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease

By LabMedica International staff writers
Posted on 09 Jul 2025

Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. More...

The symptoms of Lyme disease, such as fever, headache, fatigue, chills, joint pain, and in some cases, a rash, make it challenging to diagnose quickly and accurately. Standard testing methods may not provide full diagnostic coverage, especially since IgM antibodies appear first and indicate a current or recent infection, while IgG antibodies, appearing weeks later, can suggest chronic or past infection. Using both IgM and IgG tests allows for full diagnostic coverage of a disease. Now, a more sensitive Lyme disease test that includes both IgM and IgG antibody detection improves the ability to detect the disease at various stages.

The iDart Lyme IgM and IgG ImmunoBlot Kits from ID-FISH Technology (Milpitas, CA, USA) feature 26 and 31 Lyme antigen bands, respectively, surpassing the antigen bands available in other Lyme immunoblot tests on the market. The inclusion of multiple antigens, including Osp A (P31) and Osp B (P34), improves the sensitivity of the test, providing a more accurate diagnosis of Lyme disease in suspected patients. The test works by identifying specific Lyme disease antigens in blood samples, which enhances diagnostic accuracy without compromising specificity.

The iDart Lyme IgM and IgG ImmunoBlot test kits were validated and have received FDA clearance, marking a significant advancement in Lyme disease diagnostics. The tests offer new criteria for interpreting results, which differ from the CDC criteria. The inclusion of bands 31 and 34 makes these the only FDA-cleared Lyme serological tests to feature these bands. ID-FISH Technology plans to start shipping these kits in late 2025, with laboratories as the primary target customers. The future goal is to expand the use of these tests to provide more reliable diagnostics for Lyme disease.

"We are delighted to have received FDA clearance for our Lyme kits," said Dr. Jyotsna Shah, PhD, Chief Scientific Officer of ID-FISH Technology. "The R&D team at ID-FISH has worked tirelessly on making sure that we deliver the most accurate tests possible for the detection of Lyme disease. We look forward to working with partners to get these tests to patients."

Related Links:
ID-FISH Technology


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.